General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
In combination with enfortumab vedotin, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.
Last updated May 26, 2025
Status:
Concluded with an LOI
Manufacturer:
Nora Pharma Inc.
Indication:
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.
Last updated May 23, 2025
Status:
Concluded with an LOI
Manufacturer:
Horizon Therapeutics Canada
Indication:
Neuromyelitis optica spectrum disorder (NMOSD)
Last updated May 12, 2025
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Polyneuropathy in hereditary transthyretin-mediated amyloidosis
Last updated May 7, 2025
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Hidradenitis Suppurativa
Last updated May 1, 2025
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Ulcerative Colitis
Last updated April 29, 2025
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Last updated April 28, 2025
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
For the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.
Last updated April 25, 2025
Status:
Concluded with an LOI
Manufacturer:
Jamp Pharma Corporation
Indication:
Ulcerative Colitis and Crohn's Disease
Last updated April 25, 2025
Enhertu (concluded with pTAP LOI) (trastuzumab deruxtecan)
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
As monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen
Last updated April 24, 2025